We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

125 hedge funds and large institutions have $514M invested in Adamas Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 47 increasing their positions, 33 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more call options, than puts

Call options by funds: $4.46M | Put options by funds: $2.43M

42% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 33

1% less funds holding

Funds holding: 126 → 125 (-1)

4% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 24

24% less capital invested

Capital invested by funds: $676M → $514M (-$162M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
125
Holders Change
-1
Holders Change %
-0.79%
% of All Funds
2.86%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
23
Increased
47
Reduced
33
Closed
24
Calls
$4.46M
Puts
$2.43M
Net Calls
+$2.03M
Net Calls Change
+$53K

Top Buyers

Rank Fund Capital Flow
1
Macquarie Group
Macquarie Group
Australia
+$11.1M
2
SAM
Sectoral Asset Management
Quebec, Canada
+$8.64M
3
AAP
Ardsley Advisory Partners
Connecticut
+$5.87M
4
BWCA
Brenner West Capital Advisors
New York
+$5.25M
5
Marshall Wace
Marshall Wace
United Kingdom
+$5.06M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$17.6M
2
PA
Perceptive Advisors
New York
-$15.5M
3
State Street
State Street
Massachusetts
-$8.33M
4
GTC
Ghost Tree Capital
New York
-$7.62M
5
SFM
Sphera Funds Management
Israel
-$5.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$4.98M +$56.1K +2,390 +1%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$4.36M +$449K +19,104 +10%
Marshall Wace
28
Marshall Wace
United Kingdom
$4.32M +$5.06M +215,589 New
GPCM
29
Granite Point Capital Management
Massachusetts
$3.9M -$174K -7,400 -4%
Axa
30
Axa
France
$3.82M +$94.8K +4,037 +2%
BBA
31
Baker Bros. Advisors
New York
$3.46M – – –
Deutsche Bank
32
Deutsche Bank
Germany
$2.8M +$2.11M +89,731 +179%
BOS
33
Bingham Osborn & Scarborough
California
$2.61M – – –
American Century Companies
34
American Century Companies
Missouri
$2.51M +$622K +26,503 +27%
Fisher Asset Management
35
Fisher Asset Management
Washington
$2.37M -$658K -28,012 -19%
Dimensional Fund Advisors
36
Dimensional Fund Advisors
Texas
$2.21M +$2.59M +110,338 New
Bank of America
37
Bank of America
North Carolina
$2.16M -$656K -27,937 -21%
Citigroup
38
Citigroup
New York
$2.01M +$783K +33,366 +50%
O
39
OrbiMed
New York
$2M +$2.35M +100,000 New
ORI
40
Oak Ridge Investments
Illinois
$1.9M -$396K -16,851 -15%
State of New Jersey Common Pension Fund D
41
State of New Jersey Common Pension Fund D
New Jersey
$1.87M – – –
Goldman Sachs
42
Goldman Sachs
New York
$1.86M +$1.53M +65,024 +234%
First Trust Advisors
43
First Trust Advisors
Illinois
$1.7M +$1.99M +84,793 New
BAMCO Inc
44
BAMCO Inc
New York
$1.57M -$3.1M -131,984 -63%
KA
45
Kerrisdale Advisers
Florida
$1.46M – – –
3C
46
361 Capital
Colorado
$1.42M +$1.66M +70,817 New
DCM
47
Dupont Capital Management
Delaware
$1.4M -$332K -14,140 -17%
Allianz Asset Management
48
Allianz Asset Management
Germany
$1.28M +$200K +8,507 +15%
TA
49
Teachers Advisors
New York
$1.22M +$584K +24,859 +69%
HSBC Holdings
50
HSBC Holdings
United Kingdom
$1.18M +$1.38M +58,904 New
1
2
3 4 5

ADMS Hedge Fund Activity: Q3 2018 in Review

125 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2018, worth a combined $514M — down 24% from $676M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of ADMS and 23 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 47 added.

The largest buyer was Macquarie Group, adding an estimated $11.1M. The largest seller was Fidelity Investments, cutting an estimated $17.6M.

  • 125 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2018, down from 126 in Q2 2018.
  • Funds reported $514M of Adamas Pharmaceuticals stock for Q3 2018, down 24% quarter-over-quarter.
  • 23 funds opened new Adamas Pharmaceuticals positions in Q3 2018 and 24 closed out, a net change of -1 holder.
  • The largest Adamas Pharmaceuticals buyer in Q3 2018 was Macquarie Group, an estimated $11.1M added.
  • The largest Adamas Pharmaceuticals seller in Q3 2018 was Fidelity Investments, an estimated $17.6M sold.

Based on aggregated 13F filings for Q3 2018.